Which has higher earnings & valuation, ARVN or ADCT?

Arvinas has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 2.30 -$80.80M $0.10 93.60 ADC Therapeutics $81.36M 1.57 -$142.62M -$0.66 N/A

Is ARVN or ADCT more profitable?

Arvinas has a net margin of 2.94% compared to ADC Therapeutics' net margin of -121.77%. Arvinas' return on equity of 1.91% beat ADC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas 2.94% 1.91% 1.29% ADC Therapeutics -121.77% N/A -32.74%

Does the media favor ARVN or ADCT?

In the previous week, Arvinas and Arvinas both had 3 articles in the media. Arvinas' average media sentiment score of 0.94 beat ADC Therapeutics' score of 0.54 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZURA or ADCT more profitable?

Zura Bio has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% ADC Therapeutics -121.77% N/A -32.74%

Does the media refer more to ZURA or ADCT?

In the previous week, ADC Therapeutics had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Zura Bio. ADC Therapeutics' average media sentiment score of 0.54 beat Zura Bio's score of 0.40 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STTK or ADCT?

In the previous week, ADC Therapeutics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 3 mentions for ADC Therapeutics and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat ADC Therapeutics' score of 0.54 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EIKN or ADCT more profitable?

Eikon Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A ADC Therapeutics -121.77% N/A -32.74%

Does the media favor EIKN or ADCT?

In the previous week, Eikon Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Eikon Therapeutics and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.54 beat Eikon Therapeutics' score of -0.30 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADC Therapeutics (ADCT) Competitors

$1.00 +0.04 (+3.89%)

As of 08/21/2026 03:58 PM Eastern

Compare

ADCT vs. ARVN, ZURA, STTK, EIKN, and NGNE

Should you buy ADC Therapeutics stock or one of its competitors? ADC Therapeutics's main competitors and comparable companies include Arvinas (ARVN), Zura Bio (ZURA), Shattuck Labs (STTK), Eikon Therapeutics (EIKN), and Neurogene (NGNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ADC Therapeutics compare to Arvinas?

Arvinas (NASDAQ:ARVN) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

95.2% of Arvinas shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 7.3% of Arvinas shares are held by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arvinas has a net margin of 2.94% compared to ADC Therapeutics' net margin of -121.77%. Arvinas' return on equity of 1.91% beat ADC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
ADC Therapeutics	-121.77%	N/A	-32.74%

Arvinas has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.30	-$80.80M	$0.10	93.60
ADC Therapeutics	$81.36M	1.57	-$142.62M	-$0.66	N/A

Arvinas has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market.

In the previous week, Arvinas and Arvinas both had 3 articles in the media. Arvinas' average media sentiment score of 0.94 beat ADC Therapeutics' score of 0.54 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas currently has a consensus target price of $14.17, suggesting a potential upside of 51.35%. ADC Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 401.30%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Arvinas beats ADC Therapeutics on 14 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Zura Bio has higher earnings, but lower revenue than ADC Therapeutics. Zura Bio is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
ADC Therapeutics	$81.36M	1.57	-$142.62M	-$0.66	N/A

Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

Zura Bio has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
ADC Therapeutics	-121.77%	N/A	-32.74%

Zura Bio presently has a consensus target price of $17.00, suggesting a potential upside of 190.60%. ADC Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 401.30%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADC Therapeutics had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Zura Bio. ADC Therapeutics' average media sentiment score of 0.54 beat Zura Bio's score of 0.40 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ADC Therapeutics beats Zura Bio on 9 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Shattuck Labs has higher earnings, but lower revenue than ADC Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	755.71	-$48.81M	-$0.51	N/A
ADC Therapeutics	$81.36M	1.57	-$142.62M	-$0.66	N/A

In the previous week, ADC Therapeutics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 3 mentions for ADC Therapeutics and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat ADC Therapeutics' score of 0.54 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs presently has a consensus price target of $12.13, indicating a potential upside of 61.02%. ADC Therapeutics has a consensus price target of $5.00, indicating a potential upside of 401.30%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Shattuck Labs has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
ADC Therapeutics	-121.77%	N/A	-32.74%

Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Summary

Shattuck Labs beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

ADC Therapeutics has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
ADC Therapeutics	$81.36M	1.57	-$142.62M	-$0.66	N/A

Eikon Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
ADC Therapeutics	-121.77%	N/A	-32.74%

In the previous week, Eikon Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Eikon Therapeutics and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.54 beat Eikon Therapeutics' score of -0.30 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.1% of ADC Therapeutics shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eikon Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 119.49%. ADC Therapeutics has a consensus price target of $5.00, indicating a potential upside of 401.30%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

ADC Therapeutics beats Eikon Therapeutics on 8 of the 13 factors compared between the two stocks.

How does ADC Therapeutics compare to Neurogene?

ADC Therapeutics (NYSE:ADCT) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, ADC Therapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for ADC Therapeutics and 0 mentions for Neurogene. Neurogene's average media sentiment score of 0.89 beat ADC Therapeutics' score of 0.54 indicating that Neurogene is being referred to more favorably in the news media.

Company	Overall Sentiment
ADC Therapeutics	Positive
Neurogene	Positive

Neurogene has lower revenue, but higher earnings than ADC Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.57	-$142.62M	-$0.66	N/A
Neurogene	$930K	831.17	-$90.35M	-$5.03	N/A

ADC Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 401.30%. Neurogene has a consensus target price of $83.67, indicating a potential upside of 116.58%. Given ADC Therapeutics' higher possible upside, equities research analysts plainly believe ADC Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

ADC Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

Neurogene has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Neurogene	N/A	-45.10%	-41.00%

Summary

Neurogene beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$127.23M	$4.01B	$7.37B	$24.30B
Dividend Yield	N/A	3.64%	2.53%	3.70%
P/E Ratio	-1.51	11.62	272.60	30.31
Price / Sales	1.57	1,338.17	618.96	19.89
Price / Cash	N/A	105.14	78.62	32.49
Price / Book	-0.56	16.80	13.05	6.77
Net Income	-$142.62M	-$12.50M	$3.47B	$1.07B
7 Day Performance	-0.76%	3.29%	2.09%	-0.65%
1 Month Performance	-18.65%	8.23%	6.64%	3.38%
1 Year Performance	-68.49%	55.05%	25.02%	14.90%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	3.5355 of 5 stars	$1.00 +3.9%	$5.00 +401.3%	-68.5%	$127.23M	$81.36M	N/A	310
ARVN Arvinas	3.0972 of 5 stars	$8.87 -1.3%	$14.17 +59.6%	+27.9%	$571.65M	$262.60M	88.61	420
ZURA Zura Bio	2.5176 of 5 stars	$5.89 +4.7%	$10.75 +82.4%	+191.0%	$556.95M	N/A	N/A	3
STTK Shattuck Labs	3.7497 of 5 stars	$7.17 +0.5%	$12.63 +76.0%	+684.4%	$550.26M	$1M	N/A	100	Positive News
EIKN Eikon Therapeutics	2.1515 of 5 stars	$10.13 +4.1%	$25.20 +148.7%	N/A	$547.19M	N/A	N/A	384	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. ARVN, ZURA, STTK, EIKN, and NGNE

How does ADC Therapeutics compare to Arvinas?

Summary

How does ADC Therapeutics compare to Zura Bio?

Summary

How does ADC Therapeutics compare to Shattuck Labs?

Summary

How does ADC Therapeutics compare to Eikon Therapeutics?

Summary

How does ADC Therapeutics compare to Neurogene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. ARVN, ZURA, STTK, EIKN, and NGNE

How does ADC Therapeutics compare to Arvinas?

Do institutionals & insiders hold more shares of ARVN or ADCT?

Is ARVN or ADCT more profitable?

Which has higher earnings & valuation, ARVN or ADCT?

Which has more volatility and risk, ARVN or ADCT?

Does the media favor ARVN or ADCT?

Do analysts prefer ARVN or ADCT?

Summary

How does ADC Therapeutics compare to Zura Bio?

Which has better earnings & valuation, ZURA or ADCT?

Which has more risk & volatility, ZURA or ADCT?

Is ZURA or ADCT more profitable?

Do analysts recommend ZURA or ADCT?

Does the media refer more to ZURA or ADCT?

Do insiders and institutionals hold more shares of ZURA or ADCT?

Summary

How does ADC Therapeutics compare to Shattuck Labs?

Which has stronger valuation & earnings, STTK or ADCT?

Does the media prefer STTK or ADCT?

Do analysts recommend STTK or ADCT?

Do insiders & institutionals have more ownership in STTK or ADCT?

Is STTK or ADCT more profitable?

Which has more risk and volatility, STTK or ADCT?

Summary

How does ADC Therapeutics compare to Eikon Therapeutics?

Which has higher earnings & valuation, EIKN or ADCT?

Is EIKN or ADCT more profitable?

Does the media favor EIKN or ADCT?

Do insiders and institutionals believe in EIKN or ADCT?

Do analysts recommend EIKN or ADCT?

Summary

How does ADC Therapeutics compare to Neurogene?

Do insiders & institutionals have more ownership in ADCT or NGNE?

Does the media prefer ADCT or NGNE?

Which has better earnings and valuation, ADCT or NGNE?

Do analysts recommend ADCT or NGNE?

Which has more volatility & risk, ADCT or NGNE?

Is ADCT or NGNE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools